R
86.70
-2.34 (-2.63%)
| 前收盘价格 | 89.04 |
| 收盘价格 | 89.60 |
| 成交量 | 1,105,405 |
| 平均成交量 (3个月) | 740,154 |
| 市值 | 5,694,481,920 |
| 价格/销量 (P/S) | 39.10 |
| 股市价格/股市净资产 (P/B) | 300.55 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2025 |
| 营业毛利率 | -123.28% |
| 营业利益率 (TTM) | -143.73% |
| 稀释每股收益 (EPS TTM) | -2.80 |
| 季度收入增长率 (YOY) | 25.90% |
| 总债务/股东权益 (D/E MRQ) | 69.65% |
| 流动比率 (MRQ) | 3.30 |
| 营业现金流 (OCF TTM) | -113.49 M |
| 杠杆自由现金流 (LFCF TTM) | -96.71 M |
| 资产报酬率 (ROA TTM) | -51.33% |
| 股东权益报酬率 (ROE TTM) | -150.20% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Rhythm Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
-0.2
| 分析师共识 | 1.5 |
| 内部交易活动 | -4.0 |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.20 |
|
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.67% |
| 机构持股比例 | 107.02% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Baker Bros. Advisors Lp | 31 Mar 2025 | 5,604,483 |
| Nea Management Company, Llc | 31 Mar 2025 | 2,909,956 |
| Westfield Capital Management Co Lp | 31 Mar 2025 | 1,341,092 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 129.00 (Wells Fargo, 48.79%) | 购买 |
| 中 | 95.00 (9.57%) | |
| 低 | 84.00 (JMP Securities, -3.11%) | 购买 |
| 平均值 | 101.29 (16.83%) | |
| 总计 | 7 购买 | |
| 平均价格@调整类型 | 81.21 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| B of A Securities | 10 Jul 2025 | 95.00 (9.57%) | 购买 | 89.04 |
| Leerink Partners | 10 Jul 2025 | 102.00 (17.65%) | 购买 | 89.04 |
| 07 Jul 2025 | 88.00 (1.50%) | 购买 | 66.39 | |
| Oppenheimer | 10 Jul 2025 | 110.00 (26.87%) | 购买 | 89.04 |
| Wells Fargo | 10 Jul 2025 | 129.00 (48.79%) | 购买 | 89.04 |
| Needham | 09 Jul 2025 | 95.00 (9.57%) | 购买 | 89.00 |
| 07 May 2025 | 72.00 (-16.96%) | 购买 | 64.63 | |
| JMP Securities | 26 Jun 2025 | 84.00 (-3.11%) | 购买 | 61.45 |
| Stifel | 29 May 2025 | 94.00 (8.42%) | 购买 | 61.88 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| CRAMER PAMELA J. | - | 89.00 | -15,572 | -1,385,908 |
| GARFIELD ALASTAIR | - | 66.92 | -1,319 | -88,267 |
| GERMAN CHRISTOPHER PAUL | - | 89.00 | -3,817 | -339,713 |
| SHULMAN JOSEPH | - | 89.00 | -7,969 | -709,241 |
| SMITH HUNTER C | - | 89.00 | -42,120 | -3,748,680 |
| 累积净数量 | -70,797 | |||
| 累积净值 ($) | -6,271,809 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 84.58 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| CRAMER PAMELA J. | 职员 | 09 Jul 2025 | 自动卖出 (-) | 15,572 | 89.00 | 1,385,908 |
| CRAMER PAMELA J. | 职员 | 09 Jul 2025 | 执行期权 | 15,572 | - | - |
| GERMAN CHRISTOPHER PAUL | 职员 | 09 Jul 2025 | 自动卖出 (-) | 3,817 | 89.00 | 339,713 |
| GERMAN CHRISTOPHER PAUL | 职员 | 09 Jul 2025 | 执行期权 | 2,850 | - | - |
| SHULMAN JOSEPH | 职员 | 09 Jul 2025 | 自动卖出 (-) | 7,969 | 89.00 | 709,241 |
| SHULMAN JOSEPH | 职员 | 09 Jul 2025 | 执行期权 | 7,969 | - | - |
| SMITH HUNTER C | 职员 | 09 Jul 2025 | 自动卖出 (-) | 42,120 | 89.00 | 3,748,680 |
| SMITH HUNTER C | 职员 | 09 Jul 2025 | 执行期权 | 42,120 | - | - |
| SMITH HUNTER C | 职员 | 07 Jul 2025 | 执行期权 | 6,986 | - | - |
| GARFIELD ALASTAIR | 职员 | 02 Jul 2025 | 自动卖出 (-) | 1,319 | 66.92 | 88,267 |
| GARFIELD ALASTAIR | 职员 | 01 Jul 2025 | 执行期权 | 4,445 | - | - |
| 显示更多 | ||||||
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合